Abstract

Simple SummaryThe formats of bispecific antibody have been investigated for many years to enhance the stability of the structure and anti-tumor efficacy. One of the formats combining two Fabs at their C termini provides unmodified variable region and comparable activity to other fragment-based bispecific antibodies that are usually combined in a head-to-tail manner. However, the current strategy to produce the BiFab molecule is limited to a semisynthetic method that introduces unnatural amino acid to antibodies’ sequences during production. To improve the application of BiFab format in investigational biodrugs, we have applied sortase A-mediated “bio-click” chemistry to generate BiFab, for facile assembly of Fab molecules that have been expressed and stored as BiFab module candidates. The BiFabs made by our method stimulate T cell proliferation and activation with favorable in vitro and in vivo anti-tumor activit. Our results indicate that BiFab made by sortase A-mediated click chemistry could be used to efficiently generate various BiFabs with high potency, which further supports personalized tumor immunotherapy in the future.Bispecific antibodies (BsAbs) for T cell engagement have shown great promise in cancer immunotherapy, and their clinical applications have been proven in treating hematological malignance. Bispecific antibody binding fragment (BiFab) represents a promising platform for generating non-Fc bispecific antibodies. However, the generation of BiFab is still challenging, especially by means of chemical conjugation. More conjugation strategies, e.g., enzymatic conjugation and modular BiFab preparation, are needed to improve the robustness and flexibility of BiFab preparation. We successfully used chemo-enzymatic conjugation approach to generate bispecific antibody (i.e., BiFab) with Fabs from full-length antibodies. Paired click handles (e.g., N3 and DBCO) was introduced to the C-terminal LPETG tag of Fabs via sortase A mediated transpeptidation, followed by site-specific conjugation between two click handle-modified Fabs for BiFab generation. Both BiFabCD20/CD3 (EC50 = 0.26 ng/mL) and BiFabHer2/CD3 exhibited superior efficacy in mediating T cells, from either PBMC or ATC, to kill target tumor cell lines while spared antigen-negative tumor cells in vitro. The BiFabCD20/CD3 also efficiently inhibited CD20-positive tumor growth in mouse xenograft model. We have established a facile sortase A-mediated click handle installation to generate homogeneous and functional BiFabs. The exemplary BiFabs against different targets showed superior efficacy in redirecting and activating T cells to specifically kill target tumor cells, demonstrating the robustness of sortase A-mediated “bio-click” chemistry in generating various potent BiFabs. This approach also holds promise for further efficient construction of a Fab derivative library for personalized tumor immunotherapy in the future.

Highlights

  • Immunotherapies, such as chimeric antigen receptor T cells (CAR-Ts) and T-cellengaging bispecific antibodies (T-BsAbs), have revolutionized cancer treatments by leveraging the immune system [1,2]

  • GGG-PEG3-N3 or GGGPEG4-DBCO was linked onto Fabs via sortase A transpeptidation, and His-tag was released from Fabs, which spared linker-Fab components from the reaction mixture when purified by Ni-NTA affinity chromatography

  • Homogenous BiFabCD20/CD3 was obtained by size exclusion chromatography purification and further

Read more

Summary

Introduction

Immunotherapies, such as chimeric antigen receptor T cells (CAR-Ts) and T-cellengaging bispecific antibodies (T-BsAbs), have revolutionized cancer treatments by leveraging the immune system [1,2]. Compared with CAR-T cells, which are autologous T lymphocytes that are genetically engineered to express chimeric antigen receptor for specific tumor cell targeting [3], bispecific antibody can be produced relatively easier and provide off-the-shelf treatment [4,5]. This strategy has generated great interest with more than 50 T-BsAb candidates in clinical trials for a range of indicators nowadays [6]. Variable regions assembled to a format that deviate significantly from its cognate high stable IgG might compromise its affinity, especially when the N-terminus of Fvs have additional polypeptide chains that function as linkers [14,16,17]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call